Rhea-AI Summary
Iambic Therapeutics (IAM) priced its initial public offering of common stock at $16.00 per share, with all shares offered by the company.
The offering comprises 9,375,000 shares and is expected to raise $150.0 million before underwriting discounts, commissions and other offering expenses. Underwriters received a 30-day option to purchase up to an additional 1,406,250 shares at the IPO price, less underwriting discounts and commissions. Trading on the Nasdaq Global Select Market is expected to begin October 15, 2026. The offering is expected to close October 16, 2026, subject to customary closing conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags